---
title: "ENANTA Pharmaceuticals CEO Acquires 45,000 Shares"
date: "2025-02-13 09:10:00"
summary: "Reporter NameLuly Jay R.RelationshipPresident and CEOTypePurchaseAmount$256,050SEC FilingForm 4ENANTA Pharmaceuticals President and CEO, Jay R. Luly, purchased 45,000 shares of common stock on February 12, 2025, at a weighted-average price of $5.69 per share, totaling $256,050. Following this transaction, Luly directly owns 846,638 shares of ENANTA Pharmaceuticals. The purchase price ranged..."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

| Reporter Name | Luly Jay R. |
| --- | --- |
| Relationship | President and CEO |
| Type | Purchase |
| Amount | $256,050 |
| SEC Filing | [Form 4](https://www.sec.gov/Archives/edgar/data/1571211/000106299325002225/xslF345X05/form4.xml) |

ENANTA Pharmaceuticals President and CEO, Jay R. Luly, purchased 45,000 shares of common stock on February 12, 2025, at a weighted-average price of $5.69 per share, totaling $256,050. Following this transaction, Luly directly owns 846,638 shares of ENANTA Pharmaceuticals. The purchase price ranged from $5.32 to $5.86 across multiple transactions.

SEC Filing: [ENANTA PHARMACEUTICALS INC [ ENTA ] - Form 4 - Feb. 12, 2025](https://www.sec.gov/Archives/edgar/data/1571211/000106299325002225/xslF345X05/form4.xml)

[TradingView](https://www.tradingview.com/news/tradingview:4af75a5bb67a3:0-enanta-pharmaceuticals-ceo-acquires-45-000-shares/)
